Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Working capital changed -127.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change.
Current assets changed +12.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Trade receivables changed +9.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +452 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capital expenditure changed -46.8% from the comparable as-filed period.
Stock-based compensation changed -31.7% from the comparable as-filed period.
Free-cash-flow proxy changed +8.5% from the comparable as-filed period.
Inventory / revenue changed -129 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed -3.4% from the comparable as-filed period.
Operating cash flow changed +7.2% from the comparable as-filed period.
Inventory changed -22.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
SBC / revenue changed -79 basis points from the comparable as-filed period.
Free-cash-flow margin changed +191 basis points from the comparable as-filed period.
Total assets changed -3.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Shares outstanding changed +2.7% from the comparable as-filed period. The change ranks at the 12th percentile of 8 prior comparable changes.
Operating cash-flow margin changed +175 basis points from the comparable as-filed period.
Capex / revenue changed -16 basis points from the comparable as-filed period.
Research & development changed -3.0% from the comparable as-filed period.
R&D / revenue changed +5 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -58.4% from the comparable as-filed period.
Cash & equivalents changed +13.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
SBC / revenue changed -200 basis points from the comparable as-filed period.
Net income changed -19.1% from the comparable as-filed period.
Capital expenditure changed -26.8% from the comparable as-filed period.
Revenue changed -4.0% from the comparable as-filed period.
Inventory / revenue changed -129 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Inventory changed -24.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Free-cash-flow margin changed -377 basis points from the comparable as-filed period.
Operating cash-flow margin changed -382 basis points from the comparable as-filed period.
Current assets changed +7.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Total assets changed -4.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Shares outstanding changed +2.8% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes.
Research & development changed -8.6% from the comparable as-filed period.
Capex / revenue changed -5 basis points from the comparable as-filed period.
Receivables / revenue changed +74 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -53 basis points from the comparable as-filed period.
Trade receivables changed -2.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.